Affordable Premiums for Seniors Act Proposed to Extend Medicare Drug Subsidy Program

Two Democratic lawmakers have introduced a bill aimed at reversing the decision made by the Trump administration to end a Medicare prescription drug subsidy program. Representatives Kathy Castor of Florida and Terri Sewell of Alabama have announced the Affordable Premiums for Seniors Act, which seeks to extend the Medicare Part D Premium Stabilization Demonstration through 2029.

Recently, the Trump administration declared the Centers for Medicare & Medicaid Services (CMS) would conclude the program by the end of the following year. Castor expressed concern over the impact on seniors, stating, “Every trip to the grocery store and every monthly bill is increasingly painful for my older neighbors. The added strain of higher prescription drug costs is the last thing they need,” emphasizing her commitment to reversing the decision and maintaining affordable benefits.

Importance of the Program

Nearly 25 million individuals enrolled in standalone Medicare Part D prescription drug plans in 2026, according to the Kaiser Family Foundation (KFF). Without the stabilization program, beneficiaries could face significant premium increases in 2027. Retirees, already challenged by escalating housing and healthcare costs, benefit from the subsidy by keeping drug coverage affordable.

Details of the Proposed Legislation

The Affordable Premiums for Seniors Act would prevent CMS from ending the Medicare Part D Premium Stabilization Demonstration and continue it through 2029. Created in 2025 as part of reforms under the Inflation Reduction Act, this subsidy included a $2,000 cap on annual out-of-pocket prescription drug expenses. It shifted a greater share of costs onto Part D plans.

Michael Ryan, a finance expert, explained to Newsweek, “The stabilization program absorbed some of the shock while insurers adjusted to major changes in Medicare Part D. Ending it removes that cushion.” The supporters of extending the program argue it prevented steeper premium hikes and ensured predictable costs for seniors.

Impact of the Bill

If enacted, the Affordable Premiums for Seniors Act would:

• Extend the Medicare Part D Premium Stabilization Demonstration through 2029.
• Preserve federal premium assistance for standalone Medicare Part D plans.
• Aim to keep monthly prescription drug premiums lower for beneficiaries.
• Reverse the Trump administration’s decision to terminate the program after 2026.

Kevin Thompson, the CEO of 9i Capital Group, mentioned, “Lowering premiums for people at the lower end of the income spectrum, particularly those who rely heavily on prescription drugs, is a definite benefit for beneficiaries living on fixed incomes.” However, he noted the counterargument involves subsidizing insurers to maintain lower premiums rather than addressing the root issues of prescription drug and healthcare costs.

Financial Relief Provided

The Medicare Payment Advisory Commission (MedPAC) reported that the subsidy saved seniors an average of $312 in 2026. Sewell emphasized, “Ending the Part D Premium Stabilization Program could mean higher premiums and greater financial strain for millions of seniors.” The Act aims to ensure Medicare beneficiaries have stability and confidence regarding their healthcare costs.

The Trump Administration’s Perspective

CMS announced the termination of the demonstration program after reviewing 2027 plan bids and concluded insurers had significant experience operating under the revised Part D benefit. Mehmet Oz, CMS administrator, defended the decision, deeming additional subsidies as an unwarranted bailout. He stated that premiums would rise modestly, with many recipients possibly witnessing lower premiums.

CMS revealed the national base beneficiary premium for Medicare Part D will approximate $41.33 in 2027, with final premium details to be released later.

Ryan remarked, “The question moving forward is whether the market is actually ready to lose the training wheels,” as CMS suggests insurers are now equipped to manage costs sans subsidies.

What’s Next?

The bill faces an uncertain future in a Republican-controlled Congress and requires the approval of both chambers before reaching President Trump. Meanwhile, Medicare beneficiaries are anticipating the final 2027 Part D premium announcements, which will demonstrate how prescription drug coverage costs might rise post-program termination.

Thompson shared, “Without bipartisan support, extending the subsidy will be difficult,” considering the current political landscape.